obesity-congress-diabetes-congress-2018-keynote

5 / 9

O c t o b e r 1 5 - 1 6 , 2 0 1 8 | T o k y o , J a p a n
Obesity Congress 2018, Diabetes Congress 2018 & Vaccines Congress 2018
Note:
Page 20
Biomedical Research | ISSN: 0976-1683| Volume 29
2nd WORLD OBESITY CONGRESS
2nd WORLD VACCINES AND IMMUNOLOGY CONGRESS
&
&
DIABETES AND ENDOCRINOLOGY
International Conference on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Patricia Avila Fabrini, Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C5-012
VACCINATION IN PATIENTS IN USE
OF IMMUNOBIOLOGICAL DRUGS FOR
IMMUNE MEDIATED DISORDERS
Immune mediated inflammatory disease (IMID) is a concept used to describe
a group of conditions that share common inflammatory pathways. Encom-
passing disorders as ankylosing spondylitis, multiple sclerosis, psoriasis, ar-
thritis psoriatic, rheumatoid arthritis, hidradenitis suppurativa and inflamma-
tory bowel diseases, the immune dysregulation may afflict any organ system
and result in significant morbidity, reduced quality of life (QoL) and premature
death. Although the aetiology of these conditions is unknown, advances in mo-
lecular research have revealed that an imbalance in inflammatory cytokines is
central to their pathogenesis. The most convincing evidence linking the patho-
physiology and treatment of autoimmune diseases has been demonstrated
with the tumour necrosis factor‐α (TNFα) inhibitors. The therapeutic aims for
the drugs used for the treatment IMIDs are: to gain rapid control of inflamma-
tion, prevent tissue damage, improve QoL and, if possible, achieve long‐term
disease remission. This drug is named immunobiological drugs. Their use is
related to immunosuppression, and the patient who will be submitted to this
kind of treatment needs to be vaccinated. However, severe complications have
followed vaccination with live, attenuated virus vaccines and live bacterial vac-
cines among immunocompromised patients. In general, these patients should
not receive live vaccines. The aim of the present study is to standardize con-
duct of vaccination in patients using immunobiological drugs.
Biography
Patricia Avila Fabrini has an in fusional center in Belo
Horizonte, Minas Gerais, Brazil. She has her expertise
in immunobiological drugs and in her center of treat-
ment, she also has a vaccination center for the safety
use of these drugs that acts in the immune systems
of patients.
Patricia Avila Fabrini
Santhè Clinic, Brazil